Page 4 - Multicenter Study News Today

12.09.2022 - Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the presentation of data supporting the potential of omidubicel ... Seite 1

This observational follow-up study of patients from the MOMENTUM 3 randomized trial compares outcomes and overall survival in individuals who received a fully m

New research presented today at the Society of NeuroInterventional Surgery's (SNIS) 19th Annual Meeting shows that thrombectomy, a minimally invasive procedure typically reserved for treating a severe type of stroke known as large vessel occlusions (LVO), achieves positive outcomes for individuals experiencing other types of strokes.

STOCKHOLM, June 24, 2022 /PRNewswire/ -- Sobi will present new data at ISTH 2022, the 30th Congress of the International Society on Thrombosis and Haemostasis, taking place online and in London

Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 CongressSub-analyses from Kite’s ZUMA-7 study of CAR T cell therapy in second-line diffuse large B cell lymphoma includes data in patients over 65 and by tumour burden characteristicsLonger-term d...

Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite patient advocates, physicians and researchers through...

/PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization...

COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative...

The current paper, published in The Pediatric Infectious Disease Journal, examines the prevalence of anosmia in children with COVID-19 using a smell awareness survey.

In a phase 2 study, researchers are evaluating DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma.